Kura Oncology Positioned for Growth with Promising Menin Inhibitor Ziftomenib Amidst Competitor Challenges
Leerink Partners analyst Jonathan Chang has maintained their bullish stance on KURA stock, giving a Buy rating on November 12. Jonathan ...
Business Insider18h
Replimune Group’s Strategic Progress and Financial Strength Justify Buy Rating and Increased Price Target
Chang covers the Healthcare sector, focusing on stocks such as Immatics, Xencor, and Bicycle Therapeutics. According to TipRanks, Chang has an average return of -3.9% and a 36.34% success rate on ...
Indiatimes1d
India News
Mom of 3 was brutally tortured before being set ablaze in Manipur: Autopsy A horrifying incident in Manipur's Jiribam district has left the community reeling after a 31-year-old mother of three ...
Hindustan Times2d
World News
US stock futures rose while Treasury yields and the dollar fell. Traders marked up the odds of a December rate cut to around 70%, from about 60%.